TAMPA, Fla. - Pacira BioSciences, Inc. (NASDAQ:PCRX) has published results from a Phase 3 study indicating that its product, EXPAREL (bupivacaine liposome injectable suspension), significantly reduces pain and opioid consumption post-surgery. The study, which was the basis for the FDA's approval for its use as a single-dose sciatic nerve block in the popliteal fossa for bunionectomy patients, was featured in the Journal of Clinical Anesthesia.
The trial compared EXPAREL with bupivacaine HCl, a commonly used local anesthetic, and found that patients receiving EXPAREL experienced a 44% reduction in pain scores over 96 hours. Additionally, these patients consumed 61% fewer opioids and nearly a quarter of the EXPAREL group required no rescue opioids at all during the same period.
The findings are significant as they provide an option for non-opioid pain management, which is a growing clinical goal, especially for outpatient procedures. EXPAREL is the first single-dose product proven to offer superior pain control for up to four days post-surgery compared to bupivacaine HCl.
Dr. Gary Schwartz, Vice Chair of Pain and Anesthesiology at Maimonides Medical Center and lead author of the publication, emphasized the importance of EXPAREL in providing extended pain management without reliance on opioids, which can be especially beneficial for same-day surgical procedures.
The study involved 185 subjects in two parts, with the primary endpoint being the area under the curve of Numerical Rating Scale pain intensity scores from 0 to 96 hours post-surgery. Secondary endpoints included total postsurgical opioid consumption and the percentage of patients who were opioid-free during this time.
Pacira BioSciences focuses on providing non-opioid pain management solutions and is developing treatments for conditions involving the sympathetic nervous system. EXPAREL is one of their three commercial-stage non-opioid treatments.
This information is based on a press release statement from Pacira BioSciences.
InvestingPro Insights
As Pacira BioSciences, Inc. (NASDAQ:PCRX) continues to make strides in non-opioid pain management with its product, EXPAREL, investors may be keen to understand the financial health and potential growth of the company. According to InvestingPro data, Pacira has a market capitalization of approximately $1.36 billion and a Price to Earnings (P/E) ratio of 30.6 based on the last twelve months as of Q3 2023, which suggests a premium valuation compared to the industry average.
InvestingPro Tips indicate that Pacira is expected to have a high shareholder yield and that net income is anticipated to grow this year. This could be a promising sign for investors who are looking for companies with a strong potential for profitability and cash return. Additionally, three analysts have revised their earnings estimates upwards for the upcoming period, reflecting optimism about the company's future performance.
The company's gross profit margin stands at a healthy 60.54% for the last twelve months as of Q3 2023, reinforcing the company's ability to maintain profitability. It's also noteworthy that Pacira's liquid assets exceed short-term obligations, which suggests a solid liquidity position.
Investors interested in further insights can find additional InvestingPro Tips for Pacira BioSciences, Inc. at https://www.investing.com/pro/PCRX. There are a total of 9 tips available on InvestingPro, offering a deeper dive into the company's financials and projections. Moreover, readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, which includes access to more detailed analytics and investment tools.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.